TNFRSF17 and Miyoshi myopathy: Several novel drug classes have recently been approved by the US Food and Drug Administration for the treatment of relapsed/refractory MM, including the anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, idecabtagene vicleucel (ide-cel) [45], selinexor, in combination with Vd [46], and belantamab mafodotin–blmf [47].